21.08.2020 • NewsAstraZeneca

Australia Inks Vaccine Deal with AstraZeneca

The government of Australia has sealed a deal with AstraZeneca to supply enough doses of the adenovirus vector-based vaccine being developed on behalf of Oxford University to inoculate 95% of the country’s entire population of 25 million. The two sides have signed a Letter of Intentm but details on how the ambitious vaccination plan would be financed have not been revealed.

An agreement on the price of the doses is to be hammered out at a later date. Like others, the Australian agreement is contingent on the AstraZeneca/Oxford candidate completing the remaining studies successfully and receiving approval from the relevant authorities.

The British-Swedish drugmaker, which has begun Phase 2/3 clinical trials with its candidate, relying on thousands of volunteers across several countries, plans to release results of the ongoing trials later this year.

An important part of the arrangement with Australia calls for the vaccine to be produced locally. As the main manufacturer, the government has its eyes on Melbourne-based CSL Behring, a company whose roots partly part go back to the German Nobel prize-winner Emil von Behring. However, prime minister Scott Morrison said talks will be held with other Covid-19 vaccine developers about other supply deals.

CSL is currently developing a vaccine of its own, in partnership with Australia’s University of Queensland, and has told international media this project will have priority. The company aims to make at least 100 million doses of the Queensland vaccine by the end of 2021.

Under a recent funding agreement with the Coalition for Epidemic Preparedness Innovations (CEPI), founded in 2017 to develop vaccines aimed at dealing with future epidemics, CSL said it plans to scale up its own production but may also outsource.

Both vaccine candidates are produced in mammalian cells. For the AstraZeneca vaccine, CSL said it is assessing the viability of options ranging from the fill and finish of bulk product imported into to Australia through to manufacture of the vaccine candidate under license. Talks about technology transfer are said to be in progress.

AstraZeneca has already signed supply agreements with authorities in all major world regions.  The drugmaker plans to produce at least 3 billion doses of the vaccine, with the first deliveries starting as early as September this year.

 

Author: Dede Williams, Freelance Journalist

Australia has sealed a deal with AstraZeneca to supply enough doses of its...
Australia has sealed a deal with AstraZeneca to supply enough doses of its Covid-19 vaccine being developed on behalf of Oxford University to inoculate 95% of the country’s 25 million people. Plans call for local manufacture. Financial details are still to be worked out. (c) AstraZeneca

Company

Logo:

AstraZeneca

Byggrad 2/4
15185 Södertälje
Sweden

Company contact







Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

most read

Photo
19.03.2025 • News

Arkema Launches Acrylic Acid Purification Project

Arkema has announced the launch of its Carat Project at its Carling site in France. This initiative aims to enhance the capabilities and sustainability of the facility, which specializes in producing acrylic monomers and superabsorbent polymers.

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.

Photo
22.04.2025 • News

BASF Divests Two Joint Ventures in China

BASF has divested its shares in the joint venture companies, BASF Markor Chemical Manufacturing (Xinjiang) Co., Ltd. and Markor Meiou Chemical (Xinjiang) Co., Ltd. in Korla, China, to Verde Chemical Singapore Pte. Ltd.